/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce a collaboration with.
/PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of.
SYDNEY, Sept. 9, 2022 /PRNewswire/ Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, today announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be the subject of an oral presentation at the upcoming annual congress of the European Society for Medical Oncology (ESMO), which will be held in person from 9-13 September 2022 in Paris, France. The oral presentation will summarise key findings of the completed phase II study of paxalisib in glioblastoma, which was previously the subject of a poster presentation at the American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, in June 2022. The presentation will provide additional detail on pharmacokinetics and pharmacodynamics. The presentation will be delivered by Professor John de Groot, Division Chief of Neuro-Oncology at the University of California, San Francisco, one of the principal investigators on the study